Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC increased its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 59.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,189 shares of the biotechnology company’s stock after acquiring an additional 1,929 shares during the period. OneDigital Investment Advisors LLC’s holdings in Viking Therapeutics were worth $209,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. FMR LLC grew its position in shares of Viking Therapeutics by 0.6% in the fourth quarter. FMR LLC now owns 16,715,438 shares of the biotechnology company’s stock valued at $672,629,000 after purchasing an additional 96,008 shares during the period. Geode Capital Management LLC lifted its stake in Viking Therapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,880,713 shares of the biotechnology company’s stock valued at $75,704,000 after buying an additional 17,046 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Viking Therapeutics by 446.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,357,241 shares of the biotechnology company’s stock worth $54,615,000 after buying an additional 1,108,972 shares during the last quarter. Norges Bank purchased a new stake in Viking Therapeutics during the 4th quarter worth approximately $51,464,000. Finally, Alliancebernstein L.P. raised its holdings in shares of Viking Therapeutics by 7.9% during the fourth quarter. Alliancebernstein L.P. now owns 1,115,068 shares of the biotechnology company’s stock valued at $44,870,000 after acquiring an additional 81,183 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Insiders Place Their Bets

In other news, Director Sarah Kathryn Rouan acquired 1,240 shares of the company’s stock in a transaction dated Monday, March 31st. The stock was acquired at an average cost of $24.15 per share, with a total value of $29,946.00. Following the completion of the purchase, the director now owns 1,240 shares of the company’s stock, valued at $29,946. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 4.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Truist Financial reissued a “buy” rating and issued a $75.00 price objective (down from $95.00) on shares of Viking Therapeutics in a research note on Monday. Morgan Stanley dropped their target price on shares of Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Raymond James raised their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. The Goldman Sachs Group started coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They set a “neutral” rating and a $30.00 price objective for the company. Finally, Piper Sandler cut their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating for the company in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.15.

Viking Therapeutics Price Performance

NASDAQ VKTX opened at $27.94 on Wednesday. The stock has a market capitalization of $3.14 billion, a P/E ratio of -27.94 and a beta of 0.84. The firm’s 50-day moving average is $26.27 and its two-hundred day moving average is $39.98. Viking Therapeutics, Inc. has a 12 month low of $18.92 and a 12 month high of $81.86.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Viking Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. As a group, analysts anticipate that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.